Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Asian CROs On The March, But Tie-Ups Carry Risk: Analyst

This article was originally published in PharmAsia News

Executive Summary

SAN FRANCISCO - Pointing to the potential for a "perfect storm" in China and Asia with regard to contract research organizations' growth, Lehman Brothers analyst Douglas Tsao switched his metaphor to bolster the warning

You may also be interested in...



Merck China CEO Michel Vounatsos And Emerging Markets R&D Senior VP RuiPing Dong On Provincial Management: An Interview With PharmAsia News

Merck & Co. Inc. CEO Kenneth Frazier was the keynote speaker at the China Healthcare Investment Conference in Beijing March 23, stressing that his trip highlighted the place the Chinese market holds for the company's growth. After the conference, Merck, Sharpe and Dohme China President Michel Vounatsos and Merck Research Laboratory Senior VP for Emerging Markets RuiPing Dong spoke with PharmAsia News about navigating China's provincial markets and fitting China into a global R&D strategy.

Merck China CEO Michel Vounatsos And Emerging Markets R&D Senior VP RuiPing Dong On Provincial Management: An Interview With PharmAsia News

Merck & Co. Inc. CEO Kenneth Frazier was the keynote speaker at the China Healthcare Investment Conference in Beijing March 23, stressing that his trip highlighted the place the Chinese market holds for the company's growth. After the conference, Merck, Sharpe and Dohme China President Michel Vounatsos and Merck Research Laboratory Senior VP for Emerging Markets RuiPing Dong spoke with PharmAsia News about navigating China's provincial markets and fitting China into a global R&D strategy.

Pfizer, Lilly And Merck Strike Up Cancer Research Partnership In Asia

Eli Lilly, Pfizer and Merck - like many Big Pharma - are hoping to spur growth in the future by addressing unmet medical need in Asia's emerging markets. The three companies hope to accelerate research in addressing Asia's most-commonly diagnosed cancers with a non-competitive collaboration - perhaps the first of its kind in the region - to share data for the next several years

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

SC068095

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel